Fibrous dysplasia of bone

Lore & Background

Fibrous dysplasia results from post-zygotic activating mutations of the GNAS locus, which codes for the α subunit of the Gs G protein-coupled receptor. Constitutive Gsα signaling impairs differentiation and proliferation of bone marrow stromal cells, leading to replacement of normal bone and marrow with fibrous tissue. The bony trabeculae become abnormally thin and irregular. The disease is mosaic and not hereditary.

Reader's Guide

Fibrous dysplasia is significant as a rare, nonhereditary mosaic disease that can cause substantial morbidity through fractures, deformity, pain, and nerve compression. Its clinical spectrum ranges from incidental lesions to severe disability involving vision, hearing, or mobility loss. Diagnosis relies on imaging (x-ray showing bubbly lytic lesions or ground glass appearance; CT for ground glass; MRI for cystic areas; bone scan) and biopsy. Treatment is palliative, focusing on fracture management and deformity prevention; no medications alter disease course. Intravenous bisphosphonates may help bone pain but lack clear evidence for strengthening lesions. Surgery (grafting, curettage, plates, screws) is often effective for monostotic but not polyostotic disease; intramedullary rods are preferred for lower extremity fractures. Craniofacial surgery is complicated by regrowth, and prophylactic optic nerve decompression is contraindicated. Managing associated endocrinopathies (e.g., growth hormone excess, hypophosphatemia) is critical, as untreated hormone excess worsens craniofacial disease and blindness risk, and hypophosphatemia increases pain and fractures. Though not cancer, severe cases may undergo malignant transformation to osteosarcoma or chondrosarcoma, leading some clinicians to regard it as precancerous.

Did You Know?

• Fibrous dysplasia is not hereditary; no case of genetic inheritance from parent to child has ever been recorded.
• The vast majority of clinically significant bone lesions are detectable by age 10 years, with almost no new clinically significant lesions after age 15.
• Untreated growth hormone excess in McCune–Albright syndrome may worsen craniofacial fibrous dysplasia and increase the risk of blindness.
• Prophylactic optic nerve decompression increases the risk of vision loss and is contraindicated.

The Clinical Landscape: From Silent Lesions to Devastating Disability

Fibrous dysplasia is an exceedingly rare, nonhereditary condition in which the body's normal bone and marrow are gradually supplanted by fibrous tissue, leaving behind skeletal structures that are fragile and prone to abnormal expansion. The clinical picture spans an extraordinary range: at one end sit quiet, incidental findings that never trouble the patient, while at the other lies a devastating, disabling disease that can rob someone of sight, hearing, and the ability to walk. The condition may strike a single bone, several bones, or the entire skeleton, and it can appear alone or alongside café au lait skin patches and overactive endocrine glands—a constellation known as McCune–Albright syndrome. In rarer presentations, intramuscular myxomas accompany the bone changes in what is called Mazabraud's syndrome. Although fibrous dysplasia is not itself a malignancy, severe cases can, in some instances, transform into aggressive cancers such as osteosarcoma or chondrosarcoma, prompting some clinicians to view it as a precancerous state. To date, no cure exists, and the complications that dominate patients' lives—fractures, progressive deformity, chronic pain, and nerve compression—remain the central challenges of living with this disorder.

A Mosaic Mutation and Its Cellular Consequences

At its root, fibrous dysplasia is a mosaic disorder born from a post-zygotic activating mutation in the GNAS gene, located on chromosome 20 at position q13.2 to q13.3. This gene encodes the alpha subunit of the Gs protein-coupled receptor, and when the mutation is present, it locks that signaling pathway into a permanently active state. In bone tissue, this constitutive Gsα signaling disrupts the normal maturation and controlled growth of bone marrow stromal cells. Those cells proliferate abnormally, and over time they crowd out healthy bone and marrow, filling the space with fibrous tissue instead. On biopsy, the remaining bony trabeculae appear abnormally thin and irregular—often described as bony spicules. Crucially, the condition is never inherited from a parent; no case of parent-to-child transmission has ever been documented. Beyond the skeletal damage, the affected stromal cells overproduce fibroblast growth factor-23, a hormone that regulates phosphate. The resulting excess causes the kidneys to dump phosphate into the urine, and the downstream hypophosphatemia can trigger rickets or osteomalacia, further increasing fracture risk and bone pain.

Detecting the Disease: Imaging and Definitive Diagnosis

Because fibrous dysplasia can hide in any part of the craniofacial, axillary, or appendicular skeleton, identifying it and mapping its full extent demands a layered diagnostic approach. On plain x-ray, the affected bone often shows a characteristic bubbly lytic pattern or what radiologists call a ground-glass appearance. Computed tomography sharpens that ground-glass signature and is considered highly specific for the condition, while magnetic resonance imaging excels at revealing cystic pockets filled with fluid. A whole-body bone scan, in which radioactive tracers are injected into the bloodstream, highlights damaged bone by making those areas glow more brightly; this technique is recommended for every patient in whom fibrous dysplasia is suspected, as it helps determine how widely the disease has spread. For a definitive diagnosis, a biopsy remains the gold standard: a hollow needle extracts a small sample of the affected bone for laboratory examination. Clinically, most significant lesions declare themselves during the first few years of life and continue expanding through childhood. The overwhelming majority are detectable by age ten, and very few new or clinically important lesions emerge after the patient reaches fifteen.

The Limits of Treatment and the Imperative of Supportive Care

No medication exists that can reverse or halt the underlying process of fibrous dysplasia, so management is fundamentally palliative, centered on stabilizing fractures and limiting deformity. Intravenous bisphosphonates can ease bone pain, yet there is no solid evidence that they fortify the affected bone or reduce the likelihood of future fractures. Surgical options—bone grafting, curettage, internal fixation with plates and screws—tend to work well for isolated monostotic lesions but are frequently ineffective when the polyostotic form is involved. For lower-extremity fractures and deformities, intramedullary rods are generally the preferred approach, and progressive scoliosis can be addressed with standard spinal instrumentation and fusion. Craniofacial surgery presents a particular challenge because the dysplastic tissue often regrows after the operation, so surgeons must prioritize correcting functional impairments. Prophylactic decompression of the optic nerve is contraindicated, as it paradoxically raises the risk of vision loss. Equally critical is the management of associated endocrine disorders: untreated growth hormone excess can worsen craniofacial involvement and elevate the danger of blindness, while uncorrected hypophosphatemia amplifies both pain and fracture susceptibility.